Psyence Biomedical Ltd. SEC filings PBMWW
Psyence Biomedical Ltd. has 170 filings in SEC EDGAR's recent list, going back to Aug 1, 2023. Its latest annual report, Form 20-F, was filed on Jun 22, 2026 for the period ended Mar 31, 2026. The most recent current report (Form 6-K) was filed on Oct 21, 2026. The company's fiscal year ends on March 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Sep 1, 2026 | — |
| CORRESP | Letter to the SEC | Oct 6, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 13, 2025 | — |
| EFFECT | Filing | Mar 14, 2025 | — |
| CORRESP | Letter to the SEC | Mar 13, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 11, 2025 | — |
| EFFECT | Filing | Jan 30, 2025 | — |
| CORRESP | Letter to the SEC | Jan 28, 2025 | — |
| UPLOAD | Letter from the SEC | Jan 28, 2025 | — |
| D | Filing | Jan 7, 2025 | — |
| EFFECT | Filing | Dec 31, 2024 | — |
| CORRESP | Letter to the SEC | Dec 30, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 27, 2024 | — |
| EFFECT | Filing | Nov 8, 2024 | — |
| CORRESP | Letter to the SEC | Nov 6, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 6, 2024 | — |
| EFFECT | Filing | Oct 10, 2024 | — |
| CORRESP | Letter to the SEC | Oct 8, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 7, 2024 | — |
| EFFECT | Filing | Aug 28, 2024 | — |
| CORRESP | Letter to the SEC | Aug 26, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2024 | — |
| EFFECT | Filing | Aug 15, 2024 | — |
| EFFECT | Filing | May 14, 2024 | — |
| CORRESP | Letter to the SEC | May 13, 2024 | — |
| CORRESP | Letter to the SEC | May 9, 2024 | — |
| UPLOAD | Letter from the SEC | May 8, 2024 | — |
| CORRESP | Letter to the SEC | May 6, 2024 | — |
| UPLOAD | Letter from the SEC | Apr 29, 2024 | — |
| CORRESP | Letter to the SEC | Apr 18, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 23, 2024 | — |
| CERT | Filing | Jan 26, 2024 | — |
| 8-A12B | Filing | Jan 25, 2024 | — |
| 425 | Filing | Jan 23, 2024 | — |
| 425 | Filing | Jan 17, 2024 | — |
| 425 | Filing | Nov 15, 2023 | — |
| SEC STAFF LETTER | Filing | Nov 15, 2023 | — |
| EFFECT | Filing | Nov 13, 2023 | — |
| CORRESP | Letter to the SEC | Nov 13, 2023 | — |
| CORRESP | Letter to the SEC | Nov 3, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 25, 2023 | — |
| CORRESP | Letter to the SEC | Oct 16, 2023 | — |
| SEC STAFF LETTER | Filing | Oct 11, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 4, 2023 | — |
| CORRESP | Letter to the SEC | Sep 20, 2023 | — |
| UPLOAD | Letter from the SEC | Sep 4, 2023 | — |
Showing 46 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PBM (Nasdaq), PBMWW (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- Ontario, Canada
- Headquarters
- Toronto
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 1985062
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.